Neuroendocrine tumours of the head and neck: anatomical, functional and molecular imaging and contemporary management by Subedi, N et al.
Cancer Imaging (2013) 13(3), 407422
DOI: 10.1102/1470-7330.2013.0034
REVIEW
Neuroendocrine tumours of the head and neck:
anatomical, functional and molecular imaging and
contemporary management
Navaraj Subedia, Robin Prestwichb, Fahmid Chowdhurya,c, Chirag Patela,c, Andrew Scarsbrooka,c
aDepartment of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; bDepartment of Clinical Oncology, St Jamess
Institute of Oncology, Leeds, UK; cDepartment of Nuclear Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Corresponding address: Dr Andrew Scarsbrook, Department of Nuclear Medicine, Level 1, Bexley Wing,
St Jamess University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Email: andrew.scarsbrook@leedsth.nhs.uk
Date accepted for publication 6 June 2013
Abstract
Neuroendocrine tumours (NETs) of the head and neck are rare neoplasms and can be of epithelial or non-epithelial
differentiation. Although the natural history of NETs is variable, it is crucial to establish an early diagnosis of these
tumours as they can be potentially curable. Conventional anatomical imaging and functional imaging using radio-
nuclide scintigraphy and positron emission tomography/computed tomography can be complementary for the diag-
nosis, staging and monitoring of treatment response. This article describes and illustrates the imaging features of head
and neck NETs, discusses the potential future role of novel positron-emitting tracers that are emerging into clinical
practice and reviews contemporary management of these tumours. Familiarity with the choice of imaging techniques
and the variety of imaging patterns and treatment options should help guide radiologists in the management of this
rare but important subgroup of head and neck neoplasms.
Keywords: Neuroendocrine carcinoma; head and neck malignancy; magnetic resonance imaging; positron emission tomography/
computed tomography; somatostatin receptor scintigraphy; [123I]meta-iodobenzylguanidine scintigraphy.
Introduction
Neuroendocrine tumours (NETs) of the head and neck
region are a rare and diverse group of tumours. A wide
range of nomenclature has been used to describe these
neoplasms, with limited consensus[1,2]. NETs arising in
the head and neck can be divided into two broad groups:
(1) those with epithelial differentiation including typical
carcinoid (well differentiated), atypical carcinoid (mod-
erately differentiated, including large cell carcinoma) and
small cell carcinomas (poorly differentiated, including
composite small cell carcinoma), and (2) neurally
derived tumours, including paragangliomas and olfactory
neuroblastomas[3]. Merkel cell carcinoma is an uncom-
mon primary cutaneous small cell cancer, with a predi-
lection for the head and neck region. Rarely,
neuroendocrine cancers from non-head and neck sites
can metastasize to the head and neck region; this
should be considered in the differential diagnosis
particularly if there is a previous history of neuroendo-
crine cancer[4]. For the purposes of this article, medullary
thyroid cancer and other neuroectodermal tumours,
including Ewing sarcoma, primitive neuroectodermal
tumours and mucosal melanomas, which have been
extensively reviewed elsewhere, are not considered
further.
The aim of this article is to discuss current anatomical
and functional imaging techniques in head and neck
NETs, explore novel molecular imaging techniques, par-
ticularly those using highly specific positron-emitting
radiopharmaceuticals and the role they may play in the
future, describe and illustrate the multimodality imaging
appearances of head and neck NETs and review contem-
porary patient management in each of the different
tumour types. Anatomical (cross-sectional) and func-
tional imaging using single photon and positron-emitting
radiopharmaceuticals have distinct and complementary
roles in the evaluation of head and neck NETs.
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An understanding of the range of NETs found in the
head and neck with their highly variable natural history,
in conjunction with a familiarity with the range of ima-
ging and treatment options available, will be invaluable to
help guide radiologists in the management of these rare
tumours.
Imaging techniques
Anatomical imaging
Computed tomography (CT) and magnetic resonance
imaging (MRI) are the most commonly used techniques
when imaging head and neck tumours. Ultrasonography
(US) is also widely used as the initial imaging technique
in the assessment of neck masses, largely due to its avail-
ability and avoidance of ionizing radiation, but it has
a relatively limited role in this patient cohort with
the exception of patients with head and neck
paragangliomas.
Multislice CT facilitates rapid and detailed evaluation
of the entire neck with the ability to produce multiplanar
reformatted images. A bone algorithm, in addition to a
standard soft tissue algorithm, is particularly important
for tumours that may involve the skull base. Intravenous
contrast administration is essential to delineate the mass,
or lymphadenopathy, from adjacent normal structures.
Enhancement patterns may be helpful in characterizing
some masses, such as paragangliomas.
MRI has superior soft tissue resolution, which makes it
an ideal technique for imaging head and neck masses. It
is superior to CT in defining intracranial extension of
tumours. A head or neck coil is usually required and
generally the study should include a combination of
axial and coronal T2-weighted fast spin echo (FSE)
sequences, T2-weighted fat suppression or inversion
recovery sequences and an unenhanced T1-weighted
FSE or spin echo (SE) sequence[5]. Further fat-saturated
T1-weighted SE sequences after gadolinium administra-
tion often improve characterization of the mass. The
addition of contrast-enhanced MR angiography (CE-
MRA) has incremental value in patients with head and
neck paragangliomas[6]. There is emerging evidence that
diffusion-weighted imaging (DWI) may also be a diagnos-
tic adjunct in this patient cohort but data are inconclusive
at present[7].
Functional Imaging
Functional imaging using single photon radiopharmaceu-
ticals has been used to evaluate head and neck NETs for
many years. These techniques are often complementary
to anatomical imaging, as a result of their superior spe-
cificity and the ability to perform total-body imaging,
which can identify multifocal disease or distant metasta-
ses that may otherwise evade detection. More recently,
advances in imaging hardware technology have led to the
development of hybrid scanners capable of performing
anatomical and functional imaging sequentially in the
same session. Single photon emission computed tomogra-
phy (SPECT)/CT has many established clinical applica-
tions in the field of oncology, particularly in patients with
endocrine malignancies[8]. The use of SPECT/CT in
patients with head and neck NETs provides incremental
diagnostic value with convenient and accurate co-registra-
tion of anatomical and functional data.
There have also been stepwise advances in the poten-
tial range of functional imaging techniques that can be
used to evaluate patients with NETs. In particular, there
has been significant development of a range of highly
sensitive and specific positron-emitting radiopharmaceu-
ticals, which show great promise as highly accurate
molecular imaging probes for detection and characteriza-
tion of NETs[9]. There have been simultaneous advances
in positron emission tomography (PET) scanner technol-
ogy and combined PET/CT scanners are now widely
available.
Tracers used in functional and molecular imaging of
head and neck NETs target three distinct cellular aspects:
(1) Somatostatin receptors: these are frequently overex-
pressed by NETs and the conventional agent used is
[111In]DTPA-octreotide ([111In]pentetreotide,
OctreoScan). PET tracers targeting this receptor
include 68Ga-labelled somatostatin analogue pep-
tides (68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-
DOTA-TATE)[10].
(2) Catecholamine synthesis and storage pathways:
these are relatively unique to neural crest tumours
and the conventional scintigraphic technique uses
[123I]- or [131I]-meta-iodobenzylguanidine (MIBG).
Novel PET tracers that also target this pathway
include [18F]fluorodopamine (FDA) and
[18F]fluorodihydroxyphenylalanine (FDOPA)[11].
(3) Glucose metabolism: [18F]fluoro-2-deoxy-D-glucose
(FDG) is the most widely used PET radiotracer in
clinical use today. The metabolism and biodistribu-
tion of FDG have been extensively described. FDG
is a non-physiologic glucose analogue accumulated
in tumour cells with an overexpression of glucose
transporters, which undergoes phosphorylation and
is trapped intracellularly. Uptake of FDG is inver-
sely related to the degree of tumour differentiation
and correlates with biological behaviour. FDG-PET/
CT has a specific role in imaging poorly differen-
tiated NETs with more biologically aggressive
behaviour.
There is an emerging treatment paradigm for NETs
guided by molecular imaging using some of the diagnos-
tic radionuclides described above. In patients with inop-
erable or metastatic NETs demonstrating receptor
positivity, a possible therapeutic option is to replace the
diagnostic radionuclide with a therapeutic one. For exam-
ple, 111In or 68Ga can be replaced with 90Y or 177Lu
(both emit beta radiation) and labelled with the same
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peptides. Therefore, molecular imaging and diagnosis of
the disease can be effectively followed by personalized
treatment using the same molecular imaging vectors, a
process referred to as theranostics. Consequently, soma-
tostatin receptor imaging particularly using 68Ga peptide
PET tracers shows great promise in guiding individua-
lized patient dosimetry by pre- or posttherapeutic imaging
and assessment of therapy response using quantitative
imaging[12]. There is a paucity of data on the use of
this treatment in patients with head and neck NETs at
present but there is a substantial evidence base on its
efficacy in more common NETs[13].
Laryngeal neuroendocrine carcinoma
Epithelial malignancies with neuroendocrine differentia-
tion can occur in the larynx, as in any other organ[14].
True laryngeal NETs are a rare and heterogeneous group.
Laryngeal NETs originate from laryngeal mucosal pleur-
ipotent cells and account for less than 1% of laryngeal
tumours. There is a male predilection (male/female ratio
of 3:1)[14-16]. As with squamous cell carcinoma of the
larynx, smoking is a recognized risk factor[17]. The typi-
cal clinical presentations of these tumours are hoarseness
of voice and dysphagia.
Histological identification of different tumour types is
important to understand the tumour behaviour, prognosis
and treatment planning[18]. Atypical carcinoid is the
most frequent type[14,19]. Both typical and atypical
carcinoid tumours commonly involve the supraglottic
compartment of the larynx, whereas small cell neuroen-
docrine carcinoma typically has a more homogeneous
involvement of the larynx[20,21]. Paragangliomas are of
neural origin and rarely arise in the larynx; they are dis-
cussed later in this review.
Anatomical imaging of laryngeal NETs typically
demonstrates an enhancing mass arising from the vocal
cords (Fig. 1). CT and MRI are useful to demonstrate
local extension of the disease. The findings are non-spe-
cific and cannot lead to a definitive diagnosis. Small pri-
mary NETs may only be localized by endoscopic
assessment and not by conventional anatomical imaging.
Due to the rare nature of laryngeal NETs, there is a
paucity of data on the value of functional imaging with
conventional scintigraphic agents and no data to guide
the use of emerging PET tracers described above. There
may be a role for FDG-PET/CT in patients with small
cell carcinoma of the larynx to facilitate more accurate
staging of the disease and assessment of prognosis[22,23].
The management of laryngeal NETs is determined by
histological type along with clinical and radiological stag-
ing. The preferred treatment options for localized disease
are:
(1) Carcinoid tumours of the larynx: surgical excision is
the treatment of choice for localized carcinoid
tumours of the larynx; a subtotal laryngectomy
may be suitable depending on tumour size. Lymph
node metastases are not usually seen, and hence a
neck dissection is not required[19]. Radiotherapy is
not considered an effective modality of treatment[1].
(2) Atypical carcinoid tumours of the larynx: surgical
excision is the treatment of choice for atypical car-
cinoids. By contrast with carcinoid tumours, the
incidence of neck node metastases is high[19,24]
and an elective neck dissection is justified.
Radiotherapy and chemotherapy have not been con-
sidered as effective treatment modalities[1,24]
although this has been challenged by a small more
recent series[25].
(3) Small cell tumours of the larynx: the prognosis of
these tumours is very poor, with over 90% of
patients developing distant metastatic disease[26].
It can be considered a systemic disease in a similar
manner to small cell lung cancer. Treatment is with
a combination of chemotherapy and radiotherapy.
Non-laryngeal neuroendocrine
carcinoma
In the head and neck region, NETs are most commonly
found in the larynx. Non-laryngeal NETs of the head and
Figure 1 Supraglottic neuroendocrine carcinoma. Axial
contrast-enhanced CT demonstrates asymmetrical thicken-
ing and enhancement of the right supraglottic soft tissues
(white arrow). Oedema within the prelaryngeal subcutane-
ous tissues is secondary to recent radiotherapy.
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neck are sparsely reported in the literature, occurring
most commonly in the paranasal sinuses[27]. NETs can
rarely arise in other sites, including the salivary glands
and mucosa[2]. Like laryngeal NETs, classification is
based on the degree of tumour differentiation. Correct
pathological classification is challenging; for example in
the paranasal sinuses, sinonasal neuroendocrine cancers
of epithelial origin must be differentiated from sinonasal
undifferentiated carcinomas and olfactory neuroblasto-
mas. Large cell neuroendocrine cancers, with pathologi-
cal features similar to those arising in the lung, have been
reported in salivary glands and arising from the
mucosa[2].
Paranasal sinus neuroendocrine cancer represents only
about 5% of malignancies arising in this site, and demon-
strate aggressive behaviour with a propensity for regional
and distant metastases[28]. The ethmoid sinuses and
nasal cavity are the most common sites of origin within
the paranasal sinuses[29]. Presenting symptoms overlap
with those of benign sinus disease, including epistaxis
and nasal obstruction. Partly as a result, presentation is
typically with advanced disease[28,29]. Defining an opti-
mal treatment strategy is currently impossible due to the
lack of data, with surgery, radiotherapy and chemother-
apy all potential options. The use of imaging to define
adverse features including skull base involvement helps
guide an individualized choice of treatment. Regional
recurrence rates, reported to be in the order of 25%[28],
mandate careful imaging assessment and consideration
of prophylactic treatment of the node-negative neck.
Anatomical imaging typically demonstrates a heteroge-
neously enhancing mass within one of the paranasal
sinuses with underlying bony destruction and extension
into the adjacent anatomical spaces (Fig. 2).
Appearances are often non-specific but the presence of
expansion as well as erosion of sinus walls is more
Figure 2 Right ethmoid sinus neuroendocrine carcinoma with nodal spread. (A) Axial contrast-enhanced CT and (C)
coronal short tau inversion recovery MRI demonstrates the NET (white arrows) centred in the right ethmoidal complex
without tumour extension outside the ethmoidal air cells; there is associated expansion of the sinus and bony erosion best
appreciated on CT. (B) Axial contrast-enhanced CT and (D) axial fat-suppressed T1-weighted image on Ga MRI showing
a right retropharyngeal lymph node (white arrows), which is much more conspicuous on MRI.
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suggestive of a NET than the altogether more common
squamous cell carcinoma[27]. Somatostatin receptor scin-
tigraphy (SRS) improves specificity and positive cases
are usually well-differentiated/moderately differentiated
tumours and have better clinical outcome with treatment
(Fig. 3). Conversely, lack of uptake on octreotide scinti-
graphy does not exclude the diagnosis. There are no data
in the literature on the use of other functional imaging
techniques in this rare subtype of head and neck NETs.
Paragangliomas of the head and neck
Paragangliomas are rare vascular tumours accounting for
less than 1% of head and neck tumours[30]. These neu-
roectodermal origin tumours arise from a group of tissues
(paraganglia), which in the head and neck region migrate
along the branchiomeric (of the branchial mesoderm)
distribution. Paragangliomas within the head and neck
arise mainly from four primary sites: the carotid body
at the common carotid artery bifurcation (carotid body
tumours), the jugular foramen (glomus jugulare), along
the vagus nerve (glomus vagale), and from the tympanic
branch of the ascending pharyngeal artery within the
middle ear (glomus tympanicum). Other sites, including
the larynx[1], are rare. Median age at diagnosis is around
50 years, although paragangliomas can present at any
age. Most paragangliomas are sporadic, with only 79%
having a familial cause[31]. Presenting symptoms are typ-
ically due to cranial nerve dysfunction and/or a slowly
enlarging neck mass. Only 25% of paragangliomas
secrete catecholamines[32] and less than 5% of paragan-
gliomas are malignant[33]. Malignancy is defined by the
presence of regional or distant metastases and cannot be
predicted histologically[34]. Biopsy is not usually advised
due to the risk of bleeding, and appropriate radiology is
essential for diagnosis.
Paragangliomas demonstrate early neural or blood
vessel involvement and a propensity for skull base inva-
sion and intracranial involvement. CT is the study of
choice to investigate bone involvement, whereas MRI
defines soft tissue detail, intracranial, neural and dural
involvement. On MRI, all paragangliomas exhibit a high
signal on T2-weighted imaging and a low signal on T1-
weighted imaging (Fig. 4). As with CT, they demonstrate
avid contrast enhancement. The classic salt and pepper
appearance seen on MRI relates to the presence of hyper-
intense foci (salt) interspersed with multiple areas of
signal void (pepper) due to high flow in vascular chan-
nels (Fig. 4)[35]. This feature is only reliably seen in
tumours over 1 cm in size[36].
Despite early reports of the excellent diagnostic perfor-
mance of MIBG scintigraphy in the evaluation of para-
gangliomas, the sensitivity of this technique has
sequentially decreased over time as more experience
has been accumulated[37]. The reported sensitivity
varies between 55% and 85%, although the specificity is
much higher at 95%. MIBG scintigraphy remains useful
in the diagnostic work-up of patients with paraganglio-
mas due to the wide availability of the technique and the
ability to identify patients who may be potential
Figure 3 Sphenoid sinus neuroendocrine carcinoma. (A) Axial CT (bone windows) demonstrates an expansile soft
tissue mass within the right side of the sphenoid sinus causing erosion of the right lateral wall of the sphenoid sinus
(white arrow) extending into the petrous temporal bone. (B) Anterior view from a whole-body planar [111In]DTPA-
octeotride scintigram showing low-grade tracer uptake in the region of the right sphenoid sinus (black arrow). (C) Axial,
coronal and sagittal fused SPECT/CT images from the same study confirm that there is abnormal octreotide uptake
within the sphenoid sinus NED (red cross-hairs).
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candidates for radionuclide therapy with [131I]MIBG[38].
As a cautionary note, however, a recent study reported a
high incidence of false-negative MIBG scans in patients
with malignant head and neck paragangliomas that sub-
sequently metastasized; this was particularly prevalent in
patients with the familial form of the disease[39].
SRS with [111In]DTPA-octreotide has been reported to
have a higher sensitivity than MIBG imaging in head and
neck paragangliomas[40]. Sensitivity is reduced when
there is lack of somatostatin receptor type 2 expression,
such as that seen in poorly differentiated malignant para-
gangliomas, which are less common in the head and neck
and usually familial rather than sporadic in nature. A
pitfall of this technique is the potential for false-positive
uptake related to inflammation or infection, which can
lead to interpretative errors[13]. Newer 68Ga-labelled
somatostatin analogue peptides (68Ga-DOTA-TOC,
68Ga-DOTA-NOC, 68Ga-DOTA-TATE) have shown
favourable characteristics in PET/CT imaging, with a
high affinity for somatostatin receptors and a stable
process of labelling[13]. They have shown promising
results in imaging of nonhead and neck NETs com-
pared with conventional SRS but there are no data on
their usefulness in paragangliomas. Imaging can be com-
pleted within 2 h with no need for delayed imaging on a
subsequent day, as opposed to SRS, which routinely
requires imaging at 4 h and at 24 h. However, despite
the obvious strengths, this technology has been slow to
be adopted into clinical routine in the United Kingdom
due to a combination of financial considerations, regula-
tory hurdles and logistical challenges. It is hoped these
issues can be addressed in the near future and, if so, these
agents may gradually replace the older agents for func-
tional imaging of NETs[9].
There has been sustained development and evaluation
of several PET ligands with the goal of providing a more
holistic molecular fingerprint of neural crest tumours that
encompasses other biomarkers such as tumour aggres-
siveness and molecular differentiation, which may have
an important prognostic and therapeutic significance
Figure 4 Glomus vagale in a patient with SDHD genetic mutation. (A) Maximum intensity projection PET image from
a half-body FDG-PET/CT scan demonstrates avid FDG uptake within the right parapharyngeal region (black arrow).
(B) Axial images from the same study: CT (top), PET (middle) and fused PET/CT (bottom) showing an FDG-avid
paraganglioma within the right posterior parapharyngeal space (white arrow). (C) Coronal T1 (top) and short tau
inversion recovery (bottom) images from an MRI examination in the same patient demonstrates a 2.5-cm mass situated
immediately posterior to the carotid vessels in the right parapharyngeal space consistent with a glomus vagale tumour
(paraganglioma). The bottom image shows a heterogeneous signal within the lesion with high signal interspersed with
signal void, the so-called salt and pepper appearance.
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particularly when combined with genetic and biochemi-
cal features. FDOPA-PET/CT is a promising, highly spe-
cific imaging technique for evaluation of head and neck
paragangliomas. A recent study in patients with non-
familial paragangliomas reported a sensitivity of 98%
(62/64 lesions) and specificity of 100% for FDOPA-
PET/CT, compared with MIBG sensitivity of only 53%
(34/64 lesions) and specificity of 91%[41]. Patients with
negative MIBG studies were found not to express vesic-
ular monoamine transporter expression (VMAT-1) likely
as a consequence of the poorly differentiated nature of
these tumours. Another study reported that FDOPA-PET
had a superior sensitivity of 90%, compared with MIBG-
SPECT (65%) and CT and MRI (67%)[42]. However,
more limited sensitivity of FDOPA-PET for familial
and metastatic paragangliomas has also been
reported[43].
Familial paraganglioma is associated with mutations in
the succinate dehydrogenase (SDH) gene-mitochondrial
complex involved in electron transfer and the Krebs
cycle[44]. There are four subunits (A to D) that form
the enzyme complex, and these are associated with dif-
ferent geno-phenotypic expressions of disease. Patients
with SDHB mutations are prone to malignant head and
neck paragangliomas with a high propensity for metasta-
sis, whereas SDHD mutations typically manifest with
multiple, benign head and neck paragangliomas with
very rare occurrence of metastatic disease[45]. Up to
10% of head and neck paragangliomas are reported to
be related to these hereditary mutations[46]. Limited data
exist concerning the clinical and imaging features that
distinguish sporadic from familial paragangliomas. A
recent study reported that young age, large tumour
volume, greater rate of metastatic and multifocal para-
gangliomas, higher intralesional metabolic activity on
FDG-PET, and increased CT enhancement were
observed in SDHB-related head and neck paraganglio-
mas[47]. The authors suggested that these findings may
warrant genetic screening for SDH mutations and
because SDHB-positive patients demonstrate more supra-
diaphragmatic lesions, whole-body functional imaging
may be of particular value in these patients. In another
study that evaluated 30 patients with SDHB germline
mutation-related metastatic neural crest tumours, FDG-
PET had a sensitivity of 100%, which exceeded that of
FDOPA (88%), MIBG (80%), and SRS sensitivity (81%).
A large proportion (90%) of the lesions negative on
FDOPA and MIBG were localized with FDG-PET sug-
gesting it to be the imaging study of choice in patients
with SDHB germline mutations[43]. Others have reported
that FDA-PET had the highest sensitivity (90%) for
detection of bone metastases in patients with metastatic
phaeochromocytomas and paragangliomas, followed by
bone scintigraphy (82%), CT or MRI (78%), FDG-PET
(76%) and MIBG (71%). However, in the subgroup with
SDHB mutation, the optimal imaging approaches for
bone metastases were CT and MRI (96%), bone
scintigraphy (95%), and FDG-PET (92%)[48]. It is not
possible to predict the best combination of anatomical
and functional imaging in individual patients with head
and neck paragangliomas but, in general, FDG;PET/CT
should be considered in the diagnostic work-up of SDHB
mutation carriers to provide the most accurate staging
(Fig. 5). FDOPA- or FDA-PET may provide the highest
accuracy in non-SDHB patients although there are no
cost-effectiveness data available and these tracers are lim-
ited to highly specialized centres at present.
The presentation and imaging characteristics of each of
the different sites of head and neck paraganglioma are
summarized below:
Carotid body tumours
The most common type arises from the carotid body and
accounts for over 60% of head and neck paraganglio-
mas[49]. The epicentre of this tumour is typically the
posteromedial wall of the carotid bifurcation but
growth along the wall of the external or internal carotid
arteries has also been reported[49]. They typically splay
the internal and external carotid arteries. On further dis-
ease extension, these tumours encase the carotid arteries
and extension into the skull base/intracranial cavity is
recognized[30]. The most common clinical presentation
of a carotid body paraganglioma is an insidiously enlar-
ging lateral neck mass often associated with bruit. Other
symptoms include hoarseness, stridor, tongue paresis,
vertigo, and mild dysphagia[30]. The typical CT appear-
ance of a carotid body tumour is an avidly enhancing soft
tissue mass located in the infrahyoid neck splaying the
internal and external carotid arteries (Fig. 6).
Glomus jugulare tumours
Glomus jugulare paragangliomas arise from the jugular
bulb, the tympanic branch of the glossopharyngeal nerve
(Jacobson nerve), or the auricular branch of the vagal
nerve (Arnold nerve). The tumour spreads along the path
of least resistance including mastoid air cells[50], vascular
channels[50,51], Eustachian tube[52], and neural foramina.
The prevalence of these tumours is uncertain; some
authors believe they are more common than carotid
body paragangliomas, whereas others believe carotid
body tumours are more common. Nonetheless, about
80% of all paragangliomas are either carotid body
tumours or glomus jugulare tumours[53]. Typically,
patients present with pulsatile tinnitus. Less common
manifestations include conduction deafness, vertigo,
hoarseness, and aural pain or discharge. Cranial nerve
palsies occur late in the disease progression. High-resolu-
tion CT early on in the disease process typically shows an
irregular/enlarged jugular foramen. Progressive growth of
the tumour causes a moth-eaten pattern of erosion of the
jugular foramen and mastoid (Fig. 7). Ossicular chain
destruction is common.
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Glomus vagale tumours
Vagal paragangliomas typically occur within or below the
inferior ganglion (nodose ganglion) or within the supe-
rior ganglion (jugular ganglion)[54]. These are the third
most common type of paragangliomas in the head and
neck. Typically, patients present with a painless insidious
lateral neck mass behind the angle of the mandible.
Lower cranial nerve palsies occur late in the disease pro-
cess[55]. On CT, vagal paragangliomas appear similar to
carotid body tumours but displace both internal
and external carotid arteries anteromedially (Fig. 4). In
addition, extension into the suprahyoid carotid space is
seen in approximately two-thirds of vagal paraganglio-
mas.
Glomus tympanicum tumours
The glomus tympanicum tumour is typically a small dis-
crete lesion of the cochlear promontory confined within
the tympanic cavity[56,57]. Unlike with glomus jugulare,
ossicular chain destruction is unusual[56]. These tumours,
however, may spread to the mastoid air cells, Eustachian
tube and nasopharynx[58]. Pulsatile tinnitus is a common
clinical manifestation of this tumour.
Figure 5 Metastatic head and neck paraganglioma in SDHB genetic mutation. (A) Maximum intensity projection PET
image from a half-body FDG-PET/CT scan demonstrates a plaque-like area of extremely intense FDG uptake in the right
neck around the carotid sheath (top black arrow). There are multiple foci of abnormal uptake elsewhere including the
lungs (lower black arrow) and axial skeleton, including the right scapula, ribs, sternum and numerous vertebrae.
(B) Axial images from the same study: CT (top), PET (middle) and fused PET/CT (bottom) showing a large FDG-
avid bone metastasis within the left side of the sacrum; there is little evidence of structural abnormality on the CT
component (white arrow, top).
414 N. Subedi et al.
Management of paragangliomas
Most head and neck paragangliomas demonstrate an
indolent growth pattern. One imaging study demon-
strated a median growth rate of 1.0mm/year with a
median tumour doubling time of 4 years[59]. Death
from paraganglioma is rare[60] and the aim of treatment
is to minimize/reduce morbidity rather than to improve
survival. Options for treatment include observation for
selected cases, surgery or radiotherapy. Traditionally, sur-
gery has been the preferred method of primary treatment,
with radiotherapy reserved for unresectable disease or
less fit patients. The vascularity and skull base location
of many paragangliomas make surgical management very
challenging. Preoperative embolization has been used to
reduce intraoperative blood loss and facilitate complete
resection[61]. High local control rates of series of external
beam radiotherapy and radiosurgery has challenged this
approach. A recent systematic literature review[62] sug-
gested that external beam radiotherapy or stereotactic
radiosurgery offered similar tumour control compared
with surgery, with lower risks of morbidity. Similarly, a
meta-analysis[63] of tumour control rates and treatment-
related morbidity for glomus jugulare tumours found that
radiosurgery offered superior local control with a lower
rate of cranial nerve palsy compared with surgery.
Laryngeal paragangliomas are generally treated by local
excision or partial laryngectomy[1].
Radiological investigations are key to planning both
surgical and non-surgical approaches. Choosing the
correct surgical approach requires knowledge of the
extent of invasion of adjacent structures. Similarly, the
location of steep dose gradients provided by modern
highly conformal radiotherapy or stereotactic radiosur-
gery allowing sparing of adjacent normal structures
requires excellent definition of the soft tissue and bony
extent of disease. Radiotherapy is routinely planned on
CT imaging in the treatment position. CT/MRI co-regis-
tration can be used to directly incorporate the soft tissue
definition offered by MRI into the radiotherapy planning
process[64].
Olfactory neuroblastoma
Olfactory neuroblastoma (ONB) (also known as esthe-
sioneuroblastoma) is a rare malignant neuroectodermal
tumour arising from the olfactory epithelium of the olfac-
tory ring of the superior nasal mucosa. Neuroepithelial
sensory cells found in the upper nasal cavity are thought
to be the cellular origin of these tumours[65].
Neuroectodermal carcinoma of the sinonasal tract is
also thought to arise from these specialized sensory
cells of the nasal mucosa. ONB accounts for about 2%
of all sinonasal tract tumours[66]. A bimodal age distri-
bution in the 2nd and 6th decades of life has been
described, although ONB may occur at any age. No
gender predilection has been found[66].
The presenting features of ONB relate to the pattern of
local spread. The origin of ONB is usually unilateral[67]
Figure 6 Carotid body tumour. (A) Axial maximum intensity projection image from a contrast-enhanced CT of the neck
showing a heterogeneous, hypervascular mass in the left carotid space (white arrow). (B) Sagittal reformat of the same
study shows that the lesion is positioned between the bifurcation of the common carotid artery (white arrow); this is the
typical appearance of a carotid body tumour (paraganglioma).
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and hence unilateral nasal obstruction and epistaxis can
occur in the early stage of the disease. However, patients
often present with locally advanced disease, due to local
spread through the cribriform plate into the skull base.
Symptoms of more advanced disease include headache,
rhinorrhea or visual disturbances. Occlusion of the ipsi-
lateral nasolacrimal duct may lead to epiphoria. There are
isolated cases reports of ONB presenting with Cushing
syndrome[68]. Clinical assessment may reveal a reddish-
grey pedunculated mass.
Cross-sectional imaging with CT to assess the extent of
bone destruction and MRI are recommended to define
the local extent of disease[69]. Anatomical imaging clas-
sically reveals a dumbbell-shaped mass centred at the
cribriform plate containing intracranial and nasal cavity
components (Fig. 8). Speckled calcification and bone
erosion are often seen on CT; the tumour exhibits intense
contrast enhancement. MRI demonstrates the local
extent of the soft tissue component. These tumours are
hypointense on T1 and hyperintense on T2 with marked
Figure 7 Glomus jugulare tumour. Coronal (A), sagittal (B) and axial (C) images from a contrast-enhanced CT scan
demonstrate a bilobed, expansile, hypervascular mass (white arrows) within the right base of the skull extending through
the jugular foramen into the right cerebellopontine angle. On the axial image (C), there is clear evidence of involvement
of the adjacent bones. (D) Axial T2-weighted image from an MRI scan in the same patient showing heterogeneous signal
within the lesion (white arrow) with high signal interspersed with signal void, the so-called salt and pepper appearance
that is typical of a paraganglioma (glomus jugulare).
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homogeneous contrast enhancement. Both obstructed
secretions in the adjacent sinuses and areas of cystic
degeneration appear hyperintense[70]. Anatomical ima-
ging cannot reliably differentiate these tumours from
other more common sinonasal tumours, including sino-
nasal undifferentiated carcinoma and squamous cell
carcinoma[65].
ONB usually expresses somatostatin receptors and
SRS can be used as a diagnostic adjunct[71]. However,
several brain tumours including meningiomas, gliomas
and pituitary adenomas also express somatostatin
receptors and demonstrate octreotide uptake[72]. This
radionuclide imaging is therefore not ideal for the defin-
itive diagnosis of ONB. By contrast, MIBG scintigraphy
has superior accuracy due to specific uptake and storage
mechanisms in neuroblastomas[72]. The sensitivity and
specificity of MIBG scintigraphy is very high in assess-
ment of extracranial neuroblastomas[73-76]. At present,
there are no data available on the use of novel PET
agents for assessment of ONB.
Accurate imaging assessment of the local extent of
disease including intracranial and orbital involvement is
Figure 8 Olfactory neuroblastoma (ethesioneuroblastoma). Axial (A), sagittal (B) and coronal (C) images from a
contrast-enhanced CT examination demonstrate an enhancing mass lesion centred on the right cribriform plate extend-
ing intracranially (white arrows) into the anterior cranial fossa and the right nasal cavity. (D) Sagittal T1-weighted
image from an MRI scan in the same patient showing the right nasal cavity mass extending into the anterior cranial
fossa. Biopsy confirmed an olfactory neuroblastoma.
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essential for planning treatment. The most widely recog-
nized staging system is the Kadish classification; stage A
is confined to the nasal cavity, stage B extends into the
sinuses and stage C includes skull base and intracranial
involvement and distant disease. Limited retrospective
series are the best evidence to guide the management
of these rare tumours. Outcomes have improved with
the advent of craniofacial resections[77]. Craniofacial
resection with clear margins may be adequate treatment
for early-stage disease[67]. Adjuvant radiotherapy seems
to improve local control and is routinely used for more
advanced tumours[78]. Recent case reports suggest a
potential role for neoadjuvant chemoradiotherapy
before craniofacial resection for advanced disease[79].
ONB can spread to the regional lymph nodes either at
presentation or as a site of relapse. The first echelon
lymph nodes are in the lateral retropharyngeal region,
levels Ib and II[80]. In a recent report of 26 patients
treated without elective neck radiotherapy, 7 (27%)
relapsed in the neck after a median time of 74 months;
half of these neck recurrences were associated with dis-
tant disease[80]; the authors recommended elective neck
treatment for Kadish stages B and C. Therefore, careful
radiological assessment of regional lymph nodes is essen-
tial at diagnosis; any additional role of octreotide or
MIBG-based imaging in this assessment is uncertain.
Merkel cell carcinoma
First described by Toker in 1972[81], Merkel cell carci-
noma (MCC) is an uncommon neuroendocrine (small
cell) tumour of the dermis that is characterized by aggres-
sive regional nodal invasion, distant metastases, and a
high rate of recurrence. Although it remains controver-
sial, the widely accepted origin of the tumour is the
Merkel cell, which is within the basal layer of the epider-
mis usually functioning as a chemoreceptor[82,83].
MCC commonly occurs in sun-exposed skin with over
half of these involving the head and neck region, often in
elderly whites with no reported sex predilection[84,85]. It
commonly manifests as a rapidly growing non-tender
nodule in a sun-exposed area.
The clinical manifestation determines the classification
of the disease: stage 1, cutaneous involvement; stage 2,
regional nodal invasion; stage 3, systemic metastases. The
definitive diagnosis of this tumour is based on histo-
pathology. Imaging has been shown to be beneficial in
staging, surgical guidance, therapeutic management, and
follow-up[86,87]. Clinically it is difficult to differentiate
stage 1 and 2 disease as up to two-thirds of patients
have regional lymphadenopathy at presentation and
only 731% of patients with stage 2 disease present
with palpable lymphadenopathy[88,89].
The role of lymphoscintigraphy to localize the sentinel
nodes that may be involved due to micrometastases from
MCC has been examined[90-92]. The sentinel node is the
first node to drain 99mTcfiltered sulphur colloid,
0.250.50mCi (9.2518.5 MBq) of which is injected
intradermally around the MCC site. As in melanoma;
the presence of sentinel nodes seems to be a strong indi-
cator of regional MCC disease[89,93,94]. These studies
indicate a high rate of subclinical metastases; in a small
meta-analysis, 33% of patients had a positive sentinel
node biopsy[90]. The outcome of sentinel node-negative
patients managed without adjuvant therapy seemed
favourable in this meta-analysis, although with very lim-
ited follow-up[90]. Due to the very limited size of the
studies in this area, larger prospective studies are
required to establish the role of sentinel node biopsy in
the routine management of MCC[95].
The use of imaging to exclude distant metastases is
essential before aggressive locoregional treatment with
curative intent. When pathology demonstrates a cutane-
ous small cell carcinoma, all patients should undergo
chest imaging to determine whether this is a manifesta-
tion of a metastatic small cell carcinoma of the lung or to
identify lung metastases. About one-third of patients pres-
ent with distant metastases[86]. The metastases can be
evaluated with cross-sectional imaging, which may show
hypervascular lesions with avid contrast enhancement
but the findings are non-specific (Fig. 9). SRS can be
used with greater reported sensitivity compared with ana-
tomical imaging[96] but may be limited in assessing
metastases in organs with physiological uptake of octreo-
tide such as the liver, kidneys and spleen.
The additional benefit of FDG-PET/CT compared with
conventional imaging has not yet been clearly defined in
patients with MCC. However, emerging evidence has
suggested that FDG-PET/CT may be more accurate in
staging disease compared with conventional imaging
methods including functional imaging with SRS[97-99].
The reported sensitivity and specificity of FDG-PET/
CT is as high as 89% and 100%, respectively[97]. FDG-
PET/CT may be particularly useful in restaging patients
with recurrent disease and in patients with possible
metastases at presentation[100].
For locoregionally confined disease, treatment is with
surgical excision. Achieving the recommended wide mar-
gins of 23 cm is particularly difficult in the head and
neck region[101]. This does not appear to be necessary
with the use of adjuvant wide-field radiotherapy[102].
There is a high risk of subclinical nodal disease. In the
case of MCC in the head and neck region, adjuvant
radiotherapy can be used to encompass the primary
site, potential in-transit dermal metastases, and regional
lymph node beds[95].
Conclusion
In summary, the diverse tissues of the head and neck can
give rise to a wide assortment of rare NETs. Anatomical
and functional imaging is often complementary in this
patient group and has a key role in diagnosis, staging
and guiding management decisions. With the advent of
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innovative techniques and novel tracers, the role of func-
tional and molecular imaging in this patient cohort is
likely to expand.
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